New wearable device could revolutionize kidney monitoring in ICUs

NCT ID NCT07643467

Not yet recruiting Diagnosis Sponsor: Aaron Cook Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a new wearable device that measures kidney function in real time, compared to the standard 8-hour urine collection method. Researchers will give 200 critically ill patients two dyes (relmapirazin and iohexol) and use a skin sensor to track how quickly their kidneys clear them. The goal is to see if this faster, less cumbersome method is accurate enough for routine hospital use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Relmapirazin (Lumitrace) and iohexol
What this could lead to: If successful, this could provide a faster, more accurate way to measure kidney function in hospitalized patients, helping doctors dose medications more precisely.
What could go wrong: This is an early comparison study, not a treatment trial. The device may not prove more accurate than existing methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUGMENTED RENAL CLEARANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUGMENTED RENAL CLEARANCE CRITICAL ILLNESS

Contacts and locations

Locations

UKHealthCare/University of Kentucky

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.